Improvement of cardiometabolic response

"Improvement of cardiometabolic response" is a clinical and physiological outcome rather than a specific molecular target such as a receptor, enzyme, or ion channel. It refers to the favorable modulation of a cluster of risk factors—including insulin resistance, dyslipidemia, hypertension, and visceral adiposity—that collectively increase the risk of cardiovascular disease and type 2 diabetes (PubMed, PMID: 32601138). Achieving an improved cardiometabolic response is the primary therapeutic goal of various pharmacological interventions, such as GLP-1 receptor agonists and SGLT2 inhibitors, as well as lifestyle modifications. Because it describes a systemic physiological state rather than a discrete biological entity, it is classified as a therapeutic endpoint or clinical objective. In a drug discovery context, this term identifies the desired efficacy profile of a treatment rather than the specific protein it binds to (Stat pearls, 2023).

Other names

Improved cardiometabolic profileCardiometabolic health enhancementMetabolic response improvement

This is a physiological outcome rather than a specific molecular mechanism. It results from the modulation of various targets such as GLP-1 receptors, SGLT2 transporters, or HMG-CoA reductase, leading to systemic improvements in metabolic and cardiovascular parameters (NIH, 2023).